Thomas Thestrup


Location: Copenhagen

Thomas is a Principal at Angelini Ventures, leading investments in life sciences companies. He is currently an observer board member of Damona Pharmaceuticals, Archlight Therapeutics and Cadence Neuroscience.

Thomas is passionate about life sciences, technology and entrepreneurship. He has 15 years of experience in research, health tech and the pharma industry. Prior to joining Angelini Ventures, Thomas worked for Lundbeck as Director of Corporate Business Development and Strategy. In this role, he was responsible for the in-licensing of therapeutic assets in the CNS space. In addition, he led strategic projects such as Lundbeck's Global Corporate Digital Strategy and business development for digital health. Previously, Thomas was an Associate Director for Global Business Development at UCB Pharma in Belgium, where he worked on out-licensing as well as strategic investments in the field of digital health. Thomas is also a co-founder of Jymmin, a Max Planck Health-Tech spin-off in Germany. The company creates cutting-edge music-feedback training and rehabilitation technology. Early in his career, Thomas worked as an Associate for Sunstone Life Science Ventures, a Danish Venture Capital fund based in Copenhagen. At Sunstone, Thomas invested in life science innovations such as drug development, medtech and diagnostics. Prior to joining Sunstone, Thomas worked as a Life Science consultant for the Innovation Centre Denmark in Munich, where he assisted Danish biotechnology, pharma, and MedTech start-ups and SMEs operating in the German and Swiss markets.

Thomas received his Ph.D. from the Max Planck Institute of Neurobiology and Ludwig Maximilian University in Munich, Germany, and worked as a visiting researcher at the Janelia Farm Research Campus of the Howard Hughes Medical Institute (HHMI) in Virginia.

The University of Copenhagen awarded him a Master of Science and a Bachelor of Science in Biology and Biotechnology, with experimental work at the University of Queensland, Australia.